As reported on the Times Online, the Pharmaceutical Industry giant, AstraZeneca plans to cut 1,200 UK Pharmaceutical jobs. The job cuts are a result of the company’s suspension of their research into various disease areas.
The company plans to close its research and development facility based in Leicestershire, along with another small plant in Cambridge. Pharmaceutical development work at the Avlon facility near Bristol will also cease. Some of the workers will move to the company’s Alderly Park in Cheshire which is AstraZeneca’s largest research and development plant.
This will come as disappointing news to the Government, who created the Office of Life Sciences last year in a bid to increased the number of science and pharmaceutical jobs. The head of the Office of Life Sciences, Lord Drayson, said “I’m obviously disappointed that AstraZeneca is closing Charnwood, but the announcement that Alderley Park will become one of AstraZeneca’s top three global R&D sites shows that the UK remains an attractive location for investment in pharmaceuticals.”
Earlier in the year, AstraZeneca announced that they planned to cut 8,000 jobs around the world by 2014, including 3,500 in research and development, as part of a large-scale refocusing of the business.